Alaunos Therapeutics, Inc. - Common Stock (TCRT)

NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ: TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank.

NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT).

Alaunos Therapeutics Inc. (NASDAQ:TCRT) traded at a new 52-week high today of $3.85. Approximately 130,000 shares have changed hands today, as compared to an average 30-day volume of 2.9 million shares.

Shares of Alaunos Therapeutics Inc. (NASDAQ:TCRT) traded today at $3.12, eclipsing its 52-week high. Approximately 259,000 shares have changed hands today, as compared to an average 30-day volume of 2.5 million shares.

Shares of Alaunos Therapeutics Inc. (NASDAQ:TCRT) traded at a new 52-week high today of $3.58. This new high was reached on below average trading volume as 90,000 shares traded hands, while the average 30-day volume is approximately 2.8 million shares.